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Background: Migraine is a primary headache of imprecisely known mechanism, but 
activation of the trigeminovascular system (TS) appears to be essential during the attack. 
Intensive research has recently focused on pituitary adenylate cyclase-activating poly-
peptide (PACAP) and the kynurenine systems as potential pathogenic factors.
aim: We investigated the link between these important mediators and the effects of 
kynurenic acid (KYNA) and its synthetic analog (KYNA-a) on PACAP expression in the 
rat trigeminal nucleus caudalis (TNC) in a TS stimulation model related to migraine 
mechanisms.
Methods: Adult male Sprague-Dawley rats were pretreated with KYNA, KYNA-a, the 
NMDA receptor antagonist MK-801, or saline (vehicle). Next, the trigeminal ganglion 
(TRG) was electrically stimulated, the animals were transcardially perfused following 
180 min, and the TNC was removed. In the TNC samples, 38 amino acid form of PACAP 
(PACAP1–38)-like radioimmunoactivity was measured by radioimmunoassay, the relative 
optical density of preproPACAP was assessed by Western blot analysis, and PACAP1–38 
mRNA was detected by real-time PCR.
results and conclusion: Electrical TRG stimulation resulted in significant increases of 
PACAP1–38-LI, preproPACAP, and PACAP1–38 mRNA in the TNC. These increases were 
prevented by the pretreatments with KYNA, KYNA-a, and MK-801. This is the first study 
to provide evidence for a direct link between PACAP and the kynurenine system during 
TS activation.
Keywords: migraine, trigeminovascular system, pituitary adenylate cyclase-activating polypeptide, kynurenic 
acid, MK-801
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inTrODUcTiOn
Migraine is a neurovascular primary headache disorder with 
a complex genetic background (1, 2), the pathomechanism of 
which is still not fully understood. One of the proposed mecha-
nisms of the disease is the activation and sensitization of the 
trigeminovascular system (TS). However, central sensitization 
and hyperexcitability due to excessive glutamate release are also 
suspected to be involved in the development and persistence 
of pain.
Calcitonin gene-related peptide (CGRP) is one of the main 
regulators of the TS, and the recently identified pituitary ade-
nylate cyclase-activating polypeptide (PACAP) also plays key 
roles (3–6). In migraineurs, the level of CGRP in the peripheral 
blood is increased during a migraine attack compared with the 
interictal period (4). A very similar observation has recently been 
made for PACAP as well, suggesting a potential biomarker func-
tion of PACAP in migraine (7). In addition, similarly to CGRP 
(8), intravenous administration of the 38 amino acid form of 
PACAP (PACAP1–38) provoked headache and vasodilatation, both 
in healthy participants and migraine sufferers, whereas it delayed 
migraine-like attacks only in migraineurs (9–11).
In experimental conditions, intraperitoneal administration of 
PACAP1–38 evoked marked photophobia, meningeal vasodilata-
tion and increased the number of c-fos-positive activated neu-
rons in the spinal trigeminal nucleus caudalis (TNC) in wild type, 
but not in PACAP1–38-deficient mice (12). In line with this, an 
increased concentration of PACAP1–38 was detected in the TNC 
after the activation of the TS in different animal models (13).
Interesting and promising endogenous regulators of gluta-
matergic neurotransmission include certain metabolites of the 
kynurenine pathway formed during the catabolism of tryptophan. 
Some of these metabolites are neuroactive and play essential roles 
in the modulation of N-methyl-d-aspartate glutamate receptor 
(NMDAR) function. Since glutamate-induced overexcitation 
plays a significant role in a number of neuronal diseases, the 
kynurenine system has recently become the subject of intense 
neurobiological research (14).
Kynurenic acid (KYNA), an endogenous NMDAR antagonist, 
is one of the end products of this pathway, which can dose-
dependently inhibit the activation and sensitization of TS (15). 
However, the penetration of KYNA across the blood–brain barrier 
is very limited, necessitating the development of synthetic analogs 
with potentially better pharmacokinetic properties to exploit its 
therapeutic potential. In a chemically induced animal model of 
migraine, a derivative of KYNA was able to inhibit nitroglycerin 
(NTG)-induced increase of c-fos (16) and CGRP (17) expression 
in rat TNC. Furthermore, the same KYNA analog promoted an 
anti-inflammatory response in the trigeminal ganglion (TRG) 
in a complete Freund’s adjuvant (CFA)-induced model of dural 
neuroinflammation (18).
To date, only a few studies have provided evidence for 
an association between PACAP and the NMDAR. Calcium 
influx through the NMDAR is an important mediator of 
PACAP expression, inducing gene transcription via the 
mitogen-activated protein kinase signaling cascade (19). 
PACAP has been demonstrated to enhance the functional 
coupling of neuronal nitrogen-monoxide synthase and the 
NMDAR in models of both inflammatory and neuropathic 
pain (20).
Based on all these recent findings, the aim of this study was to 
investigate a potential association between the KYNA system and 
PACAP expression, with particular regard to NMDAR activation 
and a possible novel therapeutic function for the stable KYNA 
analog in terms of its ability to influence migraine-related eleva-
tion of PACAP levels.
MaTerials anD MeThODs
animals
The study used 76 young adult (10–12 weeks old) male Sprague-
Dawley rats for the experiments; 18 intact non-stimulated ani-
mals in the control group and a total of 58 animals in the groups 
undergoing electrical stimulation of the TRG (ES-TRG) to model 
TS activation in migraine. The animals were bred and maintained 
under standard laboratory conditions on a 12- to 12-h light cycle 
at 24 ±  1°C and approximately 50% relative humidity in the 
Laboratory Animal House of the Department of Neurology. The 
rats had free access to standard rat chow and water.
ethics
All experimental procedures performed in this study complied 
fully with the guidelines of Act 1998/XXVIII of the Hungarian 
Parliament on Animal Experiments (243/1988) and with the 
recommendations of the International Association for the Study 
of Pain and European Communities Council (86/609/ECC). 
The studies were in harmony with the Ethical Codex of Animal 
Experiments and were approved by the Ethics Committee of the 
Faculty of Medicine, University of Szeged, XXIV./352/2012.
Drugs
MK-801 and KYNA were obtained from Sigma-Aldrich 
Corporation (St. Louis, MO, USA). The analog of KYNA 
(KYNA-a) was synthesized by Prof. Fülöp Ferenc and his research 
team in the Department of Pharmaceutical Chemistry, University 
of Szeged. KYNA was administered at 189.17 mg/kg body weight, 
MK-801 at 4 mg/kg body weight, and KYNA-a at 295.76 mg/kg 
body weight dose. The substances were dissolved in 1.5  ml of 
physiological saline solution, and pH was adjusted with sodium 
hydroxide and hydrogen chloride.
Abbreviations: BSA, bovine serum albumin; CFA, complete Freund’s adjuvant; 
CGRP, calcitonin gene-related peptide; EDTA, ethylenediaminetetraacetic acid; 
ES, electrical stimulation; ES-TRG, electrical stimulation of the TRG; IQRs, 
interquartile ranges; KAT II, kynurenine aminotransferase II; KYNA, kynurenic 
acid; KYNA-a, kynurenic acid synthetic analog; MAPK, mitogen-activated protein 
kinase; MCA, middle cerebral artery; MMA, middle meningeal artery; NMDAR, 
N-methyl-d-aspartate glutamate receptor; nNOS, neuronal nitrogen-monoxide 
synthase; NTG, nitroglycerin; PACAP, pituitary adenylate cyclase-activating 
polypeptide; PACAP1–38, 38 amino acid form of PACAP; PBS, phosphate-buffered 
saline; RIA, radioimmunoassay; RT-PCR, real-time polymerase chain reaction; 
SDS, sodium dodecyl sulfate; TBST, Tris-buffered saline containing Tween 20; TNC, 
trigeminal nucleus caudalis; TRG, trigeminal ganglion; TS, trigeminovascular 
system; TSH, thyroid-stimulating hormone; VIP, vasoactive intestinal polypeptide.
FigUre 1 | Structural formulae of kynurenic acid (1) and kynurenic acid 
synthetic analog (2).
TaBle 1 | The applied analytical methods and their respective subject number.
radioimmunoassay Western blot analysis real-time Pcr
Treatment electrical stimulation of the Trg (es-Trg) n Treatment es-Trg n Treatment es-Trg n
– – 7 – – 6 – – 5
0.9% NaCl + 7 0.9% NaCl + 6 0.9% NaCl + 5
Kynurenic acid synthetic analog + 7 Kynurenic acid (KYNA) + 6 KYNA + 5
– KYNA-a + 6 KYNA-a + 5
– MK-801 + 6 MK-801 + 5
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experimental Protocol
Five animal groups were created: one non-stimulated control 
group and four ES-TRG groups with different pretreatments. The 
group pretreated with vehicle (physiological saline i.v.) was used 
as the negative control, whereas that pretreated with MK-801 
(a known selective NMDAR antagonist) served as the positive 
ES-TRG control. Two additional groups were pretreated with 
KYNA and KYNA-a, respectively. The structural formulae of 
KYNA and KYNA-a are presented in Figure 1. All drugs were 
dissolved in 1.5 ml physiological saline. After optimization of pH, 
the solution was supplemented with physiological saline to a total 
volume of 2 ml.
First, the rats were anesthetized with intraperitoneal 4% 
chloral hydrate solution (10 ml/kg bw dose), and the anesthesia 
was maintained throughout the experiment. After intravenous 
administration of the pretreatments, the animals were placed in a 
stereotaxic setup. The head was fixed and the right TRG was local-
ized. A stimulating electrode (FHC concentric bipolar electrode, 
OP: 200 µm SS; IP: 50 µm Pt/lr) was introduced into the TRG, 
and electrical stimulation (ES) was performed according to the 
following parameters: duration: 30 min; stimulation rate: 10 Hz; 
current: 1 mA; stimulation mode: continuous. Results of our pre-
vious studies suggested that the concentration of PACAP1–38 in the 
central nervous system is highest 3 h after the ES-TRG; therefore, 
transcardial perfusion of the animals with 200  ml phosphate-
buffered saline was initiated 180 min after stimulation, followed 
by the dissection of the TNC (13). In the non-stimulated group, 
perfusion and dissection were carried out following anesthesia. 
After preparation, the samples were stored at −80°C until further 
use. The concentration of PACAP1–38 was measured by radioim-
munoassay (RIA), the relative optical density of preproPACAP 
was analyzed by Western blot, and the relative gene expression 
of PACAP1–38 was determined by real-time polymerase chain 
reaction (RT-PCR). The analytical methods and their respective 
subject numbers are presented in Table 1.
radioimmunoassay
The frozen samples were weighed and homogenized in 1 ml ice-
cold double-distilled water with a manual Potter homogenizer. 
The homogenates were centrifuged at 10,000 rpm for 10 min and 
then at 12,000 rpm for an additional 10 min, and 25 µl samples 
of the supernatants were used for RIA measurements. The tracer 
was mono-125I-labeled PACAP1–38 prepared in our laboratory. The 
synthetic peptide was used as the RIA standard in concentrations 
ranging from 0 to 2,000 fmol/ml. The assay buffer was composed 
of 0.05 M (pH 7.4) phosphate buffer containing 0.1 M sodium 
chloride, 0.25% (w/v) bovine serum albumin (BSA), and 0.05% 
(w/v) sodium azide. The anti-PACAP1–38 (Abcam, ab35342; Lot. 
No.: GR48676-4; 100 µl, 1:10,000 dilution), the RIA tracer (100 µl, 
3,000 cpm/tube), and the standards or samples of unknown con-
centration (100 µl) were injected into polypropylene tubes con-
taining 700 µl assay buffer (1 ml total volume). After incubation for 
48–72 h at 4°C, the antibody-bound peptide was separated from 
the free peptide by the addition of 100 µl separating solution (10 g 
charcoal, 1 g dextran, and 0.5 g commercial nonfat milk powder 
dissolved in 100 ml distilled water). Following centrifugation at 
3,000 rpm at 4°C for 20 min, the contents of the tubes were gently 
decanted, and the radioactivity of the precipitates was measured 
in a gamma counter (gamma, type: NZ310). PACAP1–38-like 
immunoreactivities of the samples were calculated from the 
calibration curve and expressed as fentomoles per milligram wet 
tissue (7, 13).
Western Blot analysis
The samples were sonicated in ice-cold buffer containing 50 mM 
Tris–HCl, 150 mM NaCl, 0.1% Igepal, 0.1% cholic acid, 2 mg/ml 
FigUre 2 | Immunoreactivity of 38 amino acid form of PACAP (PACAP1–38) in 
the TNC following electrical stimulation of the trigeminal ganglion. +p < 0.001 
vs. Control group, **p < 0.005 vs. Vehicle-treated electrical stimulation of the 
TRG (ES-TRG) group. Black lines demonstrate medians. 
Median ± interquartile range (n = 7).
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resUlTs
electrical Trg-stimulation-induced 
PacaP1–38-li increase in the Tnc is 
Prevented by KYna-a Pretreatment
Electrical stimulation of the TRG resulted in a significant 
increase of PACAP1–38-LI in the TNC of the vehicle-treated 
group (27.49 fmol/mg) compared with the intact non-stimulated 
control group (19.31 fmol/mg; p < 0.05). KYNA-a-pretreatment 
prevented this ES-TRG-evoked elevation (14.68 fmol/mg) when 
compared with the stimulated, vehicle-treated animals (p < 0.01) 
(Figure 2).
electrical Trg-stimulation-induced 
preproPacaP increase in the Tnc is 
Prevented by KYna-a, KYna, and MK-801 
Pretreatment
A significant increase in the relative optical density of pre-
proPACAP protein was observed in the vehicle-treated ES-TRG 
group (1.78) as compared with the non-stimulated control group 
(0.81; p  <  0.001). The relative optical density values of pre-
proPACAP in the ES-TRG groups pretreated with KYNA (0.74), 
KYNA-a (0.51), or MK-801 (1.04) were significantly reduced 
compared with the vehicle-treated ES-TRG group (p <  0.001). 
leupeptin, 2  mM phenylmethylsulphonyl fluoride, 1  mg/ml 
pepstatin, 2  mM ethylenediaminetetraacetic acid, and 0.1% 
sodium dodecyl sulfate (SDS). After homogenization, the 
samples were centrifuged at 12,000 rpm for 10 min at 4°C, and 
supernatants were aliquoted and stored at 20°C until use. The 
protein concentration was determined by the BCA Protein 
Assay Kit using BSA as the standard. Before protein separation, 
each sample was mixed with the sample buffer and denatured 
by boiling for 5  min. Equal amounts of protein samples 
(20 mg/lane) were separated by standard SDS polyacrylamide gel 
electrophoresis on 10% Tris–Glycine gel and electrotransferred 
onto an AmershamHybond-ECL nitrocellulose membrane 
(0.45-mm pore size). We used the Page Ruler Prestained Protein 
Ladder (10–170 kDa) to define approximate molecular weights. 
Following blotting, the membranes were blocked for 1 h at room 
temperature in Tris-buffered saline containing Tween 20 (TBST) 
and 5% nonfat dry milk powder. Subsequently, the membranes 
were incubated in TBST containing 1% nonfat dry milk and 
anti-PACAP antibody (against the C terminal; ab174982, 
dilution: 1:500, incubation parameters: overnight, 4°C), anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody 
(D16H11, dilution: 1:1,000, incubation parameters: overnight, 
room temperature). The following day, the membranes were 
incubated in TBST containing 1% nonfat dry milk powder and 
horseradish peroxidase-conjugated goat anti-rabbit secondary 
antibody (sc-2030, Santa Cruz Biotechnology) for 2 h at room 
temperature. The protein bands were revealed with SuperSignal 
West Pico Chemiluminescent Substrate using Carestream Kodak 
BioMax Light film.
real-time Pcr
For RT-PCR analysis, total RNA was isolated from the TNC 
with Trizol, according to the manufacturer’s protocol. RNA 
concentrations were determined using a MaestroNano spectro-
photometer, and the verification of RNA integrity was performed 
by gel electrophoresis, using 1% agarose gel. cDNA was synthe-
sized from 1  µg total RNA with random hexamer primers by 
RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, 
USA). The produced cDNA was stored at −20°C until further 
use. The RT-PCR was performed on a CFX 96 Real-Time System 
(Bio-Rad, USA) to detect changes in mRNA expression, using 
forward (5′-CCTACCGCAAAGTCTTGGAC-3′) and reverse 
(5′-TTGACAGCCATTTGTTTTCG-3′) primers designed for 
PACAP1–38. Thermal cycling conditions were 95°C for 2 min fol-
lowed by 40 cycles of 95°C for 10 s and 60°C 30 s. The relative 
mRNA level was calculated by the 2−ΔΔCt method. A pre-optimized 
primer and probe assay for 18S rRNA was used as an endogenous 
control (Applied Biosystems, USA).
statistical analysis
The Shapiro–Wilk test was used to determine the distribution of 
data. It shows that our data do not follow the normal distribution 
so after the Kruskal–Wallis test we used the Tukey post hoc test to 
analyze the results. A probability level of p < 0.05 was considered 
significant. Median ± interquartile ranges were represented in the 
box-plot figures.
FigUre 4 | Relative mRNA expression of 38 amino acid form of PACAP 
(PACAP1–38) in the TNC following electrical stimulation of the trigeminal 
ganglion. +p < 0.05 vs. Control group. **p < 0.01 vs. Vehicle-treated 
electrical stimulation of the TRG (ES-TRG) group. ***p < 0.001 vs. 
Vehicle-treated ES-TRG group. Black lines demonstrate medians. 
Median ± interquartile range (n = 5).
FigUre 3 | (a) Relative optical density of the preproPACAP protein in the 
TNC following electrical stimulation of the trigeminal ganglion. +++p < 0.001 
vs. Control group. ***p < 0.001 vs. Vehicle-treated electrical stimulation of the 
TRG (ES-TRG) group. ##p < 0.01 vs. kynurenic acid synthetic analog 
(KYNA-a)-treated ES-TRG group. Black lines demonstrate medians. 
Median ± interquartile range (n = 6). (B) Western blot of preproPACAP and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in the TNC.
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The difference of relative optical density between the MK-801- 
and the KYNA-a-treated groups was significant (p < 0.01). No 
significant differences were observed between the KYNA- and 
KYNA-a-treated groups. No differences were found with either 
the KYNA or MK-801-treated groups (Figures 3A,B).
electrical Trg-stimulation-induced 
increased PacaP1–38 mrna expression in 
the Tnc is Prevented by KYna-a, KYna, 
and MK-801 Pretreatment
A significant increase in the relative mRNA expression of 
PACAP1–38 was observed in the vehicle-treated ES-TRG group 
(1.162) when compared with the non-stimulated control group 
(0.987; p <  0.05). The relative mRNA expression of PACAP1–38 
in the ES-TRG groups pretreated with KYNA (0.804), KYNA-a 
(0.655; p < 0.01), or MK-801 (0.715) were significantly reduced 
compared with the vehicle-treated ES-TRG group (p <  0.001). 
Comparison of the different pharmacology-treated groups did 
not reveal any significant difference (Figure 4).
DiscUssiOn
In recent years, a number of clinical studies investigated the pos-
sible relevance of PACAP in migraine. In patients suffering from 
migraines without aura, the development of PACAP1–38-evoked 
migraine-like attack was independent of the severity of family 
load (21). In the same study, 90 min after the injection, the levels 
of numerous markers relevant in the disease (such as vasoactive 
intestinal polypeptide, prolactin, S100B, and thyroid-stimulating 
hormone) were increased in the plasma (22). In addition, mag-
netic resonance imaging angiography examinations revealed that 
PACAP1–38-induced headache was associated with prolonged 
vasodilatation of the middle meningeal artery (MMA), but not 
the middle cerebral artery (MCA) (23). The serotonin 5-HT1B/D 
receptor agonist, sumatriptan, was able to alleviate the headache, 
which mirrored the contraction of the MMA, but not the MCA, 
suggesting that PACAP1–38-induced headaches may arise from the 
extracerebral arteries (23). These human and experimental data 
suggest that PACAP may be a key molecule in the pathomecha-
nism of migraine.
Several lines of evidence reflect that abnormality of the 
kynurenine pathway plays roles in several diseases (24). Results 
of animal experiments suggest a link between the kynurenine 
pathway and migraine. Indeed, several studies have demon-
strated that the NMDAR inhibitor KYNA and its analogs have 
antinociceptive effects at the levels of both first- and second 
-order sensory neurons (25). In the animal model of CFA-
induced TS activation, KYNA and one of its derivatives both 
decreased the levels of several inflammatory mediators in the 
TRG (26). Recently, the effects of two KYNA analogs have been 
tested in the orofacial formalin model, revealing that the two 
analogs were able to inhibit the formalin-induced behavioral 
and morphological changes, and increased the concentration of 
KYNA in the rat TNC (27). Notably, systemic administration of 
NTG decreased the expression of kynurenine aminotransferase 
II in the TS of rats, an enzyme catalyzing the transformation 
of l-kynurenine to KYNA (28). In line with this, in another 
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model of TS activation, decreased KAT immunoreactivity was 
observed in mast cells, Schwann cells, and dural macrophages 
(29). Besides animal experimental data, clinical results have also 
provided evidence for the connection between the kynurenine 
system and various headache disorders, including migraine. 
Indeed, in patients suffering from cluster headache or chronic 
migraine, alterations of the kynurenine pathway were observed, 
which among others manifested in the reduction of KYNA 
concentration in the serum (30).
Based on the consistent data linking glutamatergic transmis-
sion (especially through NMDARs), the kynurenine pathway and 
PACAP to the pathogenesis of migraine, this is the first study that 
investigated the relationship between these systems. Findings that 
all proposed antagonists of the NMDAR were used here (KYNA, 
KYNA-a and the reference compound MK-801) decreased the 
expression of PACAP, both at the levels of proteome and tran-
scriptome. One of innovation of this study, that KYNA-a can 
downregulate both protein and gene expression of preproPACAP 
and PACAP1–38, suggesting that KYNA-a is a potential new drug 
in the PACAP-targeted migraine therapy in the future. However, 
the excessive reduction of PACAP expression level should be 
considered. It is crucial and hard to find the optimal concentra-
tion of this peptide, because shifting in the PACAP balance can 
lead to several symptoms (protective vs. harmful effects) due to 
the pleiotropic nature of this peptide. To reveal the long-term 
effects of PACAP in the migraine is needs further investigations. 
Our results are consistent with previous studies, which reported 
that the main mediator of PACAP gene expression is intracellular 
calcium homeostasis (19). Indeed, besides the action of voltage-
dependent calcium channels, the main inducer of PACAP gene 
expression is calcium influx through the NMDARs. The drugs 
used in our experiment block the NMDAR, thereby moderating 
the amount of calcium coming into the cell, which may result 
in decreased PACAP gene expression. The proposed mechanism 
for the regulation of PACAP gene expression is presented in 
Figure  5. The other interesting observation of this study that 
the expression levels of preproPACAP are significantly different 
between the MK-801- and the KYNA-a-treated groups, raises the 
possibility of the involvement of additional KYNA targets besides 
NMDA. Our opinion is that the differences between the variant 
drug-treated groups are based on the receptor specificity of the 
molecules. There is evidence that besides NMDAR, KYNA has an 
effect on the AMPA, kainate, aryl hydrocarbon, G protein-coupled 
receptor 35, and opiate receptor (31). Regarding KYNA-a, inves-
tigations are in process, but the exact targets and mechanisms 
of this analog have not yet been identified. Presumably, KYNA-a 
has similar targets to the base compound. Our findings raise the 
role of these receptors in migraine and draw attention to the 
importance of further examinations (Figure 5).
In other studies, associations between these systems have also 
been revealed. Immunohistochemical data suggest a possible 
interaction between glutamatergic, PACAP, and CGRP systems, 
based on the expression pattern of PACAP and glutamate in 
the TRG (32). In addition, a study investigating contextual fear 
FigUre 5 | Regulation of PACAP gene expression [based on Fukuchi et al. (19), genes to cells]. Abbreviations: AC, adenylate cylase; ATP, adenosine 
monophosphate; CaM, calmodulin; cAMP, cyclic adenosine monophosphate; CN, calcineurin; CREB, cAMP response element binding protein; CRTC1, CN/Cre 
binding protein; GPCR, G protein-coupled receptor; Gs, stimulatory G protein; KYNA, kynurenic acid; MAPK, mitogen-activated protein kinase; NMDAR, N-methyl-
d-aspartate glutamate receptor; PKC, protein kinase C; PACAP, pituitary adenylate cyclase-activating polypeptide.
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